YouTube Facebook LinkedIn Google+ Twitter Xingrss  



Horizons

November 15, 2003 | The Mirus Genomic Index, prepared exclusively for Bio·IT, is calculated as the sum of the market capitalizations of all included companies and is consequently a value-weighted index. It serves as an indicator of the financial health of the industry. The index was developed at RCW Mirus (www.merger.com), an investment banking firm, by David Hoffer and colleagues at the firm's Boston headquarters.

* Discovery Companies

Company Market  Revenues  Net Income 
Cap1 TTM2 TTM2
Celera Genomics (CRA) 812.5 88.1  (81.9)
CuraGen Corp. (CRGN) 245.7 13.4  (88.4)
deCODE Genetics Inc. (DCGN) 228.1 48.7  (119.6)
DNAPrint Genomics (DNAP.OB) 25.4 0.4  (5.2)
Exelixis Inc. (EXEL) 517.9 48.2  (90.3)
Genome Therapeutics Corp. (GENE) 77.0 15.3  (41.6)
Human Genome Sciences (HGSI) 1754.0 4.6  (223.6)
Nuvelo (NUVO) 177.4 16.2  (47.8)
Incyte Genomics Inc. (INCY) 345.7 67.0  (188.6)
Interleukin Genetics Inc. (ILGN) 69.7 0.9  (5.1)
Lexicon Genetics Inc. (LEXG) 327.7 35.1  (65.4)
Millennium Pharmaceuticals (MLNM) 4558.2 396.0  (423.6)
Myriad Genetics Inc. (MYGN) 306.1 64.3  (24.8)
Rigel Pharmaceuticals Inc. (RIGL) 198.1 14.2  (36.4)
Sequenom Inc. (SQNM) 129.6 29.6  (80.7)
Vertex Pharmaceuticals (VRTX) 939.3 118.3  (204.1)3
Q3 2003 Index = 10,712



* Tools Companies

Company Market  Revenues  Net Income 
Cap1 TTM2 TTM2
Aclara Biosciences (ACLA) 138.0 1.8 (29.7)
Affymetrix Inc. (AFFX) 1259.5 286.5 (4.0)
Applied Biosystems Group (ABI) 4576.4 1682.9 183.2 
Ciphergen Biosystems (CIPH) 340.7 50.9 (39.4)
Compugen Ltd. (CGEN) 133.8 11.0 (10.9)
Epoch Biosciences Inc. (EBIO) 58.9 11.4 (4.7)
Harvard Bioscience Inc. (HBIO) 221.3 73.5 0.5 
Illumina Inc. (ILMN) 175.8 15.9 (32.8)
Invitrogen Corp. (IVGN) 2836.2 697.4 58.9 
LION bioscience AG (ADR) (LEON) 90.4 28.0 (184.7)
Luminex Corp. (LMNX) 193.5 18.3 (14.6)
Qiagen N.V. (QGENF) 1644.3 320.9 31.2 
Third Wave Technologies (TWTI) 133.3 29.9 (32.5)
Transgenomic Inc. (TBIO) 38.9 36.3 (22.3)
Varian Inc. (VARI) 1088.6 817.7 51.8 
Q3 2003 Index = 12,930


1) Market cap is the number of shares outstanding x share price as of Sept. 30, 2003 (in $ millions).

2) TTM is trailing 12 months ending June 30, 2003, for all companies (all financials in $ millions).

3) Vertex Pharmaceuticals' net income for the first quarter of 2003 has been adjusted for a one-time $69-million gain from disposal of assets.

RCW Mirus Inc. does not assume any liability for errors or omissions.



Back to Over the Rainbow Yet? 






For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.